INTRODUCTION
============

Asthma prevalence remains at historically high levels, affecting 26 million Americans in 2011.[@b1-wjem-17-22] Asthma exacerbations were responsible for approximately two million emergency department (ED) visits in 2012.[@b2-wjem-17-22] ED visits for asthma exacerbation suggest a failure of prevention-oriented care since most asthma exacerbations are preventable with high-quality longitudinal management.[@b3-wjem-17-22],[@b4-wjem-17-22] The morbidity burden is uneven in patients presenting to the ED with asthma exacerbation -- the population at high risk. In a previous multicenter study of ED patients with asthma exacerbation during 1997--1998,[@b5-wjem-17-22] we found that uninsured adults received suboptimal chronic asthma care (e.g., lower inhaled corticosteroid \[ICS\] use) and had higher chronic asthma severity (e.g., frequent ED visits). Despite a substantial ongoing burden of asthma-related ED visits, there have been no recent efforts to examine chronic and acute asthma management disparities by insurance status in this population. To address the knowledge gap, using data from a multicenter observational study of ED patients with asthma exacerbation, we investigated whether chronic asthma severity, guideline-recommended chronic asthma care, and acute asthma management differ by insurance status.

METHODS
=======

This is a secondary analysis of data from a multicenter chart review study that characterized adult ED patients with asthma exacerbation, as part of the Multicenter Airway Research Collaboration (MARC).[@b6-wjem-17-22] The study setting, methods of measurement, and collected variables have been reported previously.[@b7-wjem-17-22]--[@b13-wjem-17-22] Briefly, we recruited EDs by inviting sites that had participated in the earlier MARC study that evaluated ED patients with asthma exacerbation during 1996 to 2001.[@b5-wjem-17-22],[@b14-wjem-17-22],[@b15-wjem-17-22] A total of 48 EDs across 23 U.S. states completed the current study.

Using the ICD-9-CM code 493.xx,[@b16-wjem-17-22] each site identified all visits with a primary ED or hospital discharge diagnosis of asthma during a 12-month period, from January 1, 2011, to December 31, 2012 (i.e., sites had 24-month window from which to select the 12-month study period) among patients aged 18 to 54 years with a history of physician-diagnosed asthma. Onsite chart abstractors reviewed medical records (ED, inpatient, primary care physician, and/or specialist records) of 40 patients who were randomly selected by the EMNet Coordinating Center at Massachusetts General Hospital. In the case of repeat visits, we only included the first randomly sampled ED visit. This approach was also used in other MARC studies.[@b17-wjem-17-22],[@b18-wjem-17-22] Two hospitals each examined an additional 40 randomly selected patients to obtain a total of 2,000 patients.

Data abstraction was performed with a standardized form and included patients' demographics, primary insurance type, estimated household income, chronic asthma factors, current asthma medications, specialty care status, details of the current asthma exacerbation, asthma management in ED or at discharge, and disposition. We estimated household income using home ZIP codes.[@b19-wjem-17-22] Specialty care was defined as outpatient asthma care by an allergist/immunologist, pulmonologist, or other physician specifically focusing on asthma care (e.g., a general internist who is director of the local asthma center). All abstracters were trained with a one-hour online lecture, followed by the completion of two practice medical records, which were evaluated with a "criterion standard." If a reviewer's accuracy was \<80% per medical record, the reviewer was retrained.

The outcome measures were 1) chronic asthma severity (as measured by ≥2 ED visits in a one-year period);[@b7-wjem-17-22],[@b20-wjem-17-22] 2) guideline-recommended chronic asthma care (i.e., use of ICS and evaluation by an asthma specialist) prior to the index ED visit;[@b3-wjem-17-22],[@b4-wjem-17-22] and 3) acute asthma management (i.e., use of systemic corticosteroid in the ED and initiation of ICS at ED discharge). Frequency of ED visits with acute asthma during the preceding one year from the index ED visit was measured by reviewing the medical records (not only ED records but also inpatient, primary care physician, and/or specialist records) for each patient. Specialty care was defined as outpatient asthma care by an allergy/immunologist, pulmonologist, or other physician focusing on asthma care (e.g., a general internist who is director of the local asthma center).

For the purpose of this analysis, we classified patients into three groups based on their primary insurance status: private insurance, public insurance (e.g., Medicaid, Medicare), and no insurance.[@b5-wjem-17-22],[@b14-wjem-17-22],[@b15-wjem-17-22] To examine the association of insurance status with each outcome, we constructed logistic regression models adjusting for age, sex, race/ethnicity, estimated household income, and history of hospitalization and intubation for asthma exacerbation. We used the generalized estimating equations to account for patient clustering within EDs. All analyses were performed with SAS 9.4 (SAS Institute, Cary, NC). The institutional review board of each participating hospital approved the study.

RESULTS
=======

Of 2,000 ED patients with asthma exacerbation, 1,928 patients (96%) had data on insurance status and were included in the analysis. The analytic and non-analytic cohorts were similar in their age, sex, chronic asthma factors and management, ED asthma management, and disposition ([Appendix 1](#s1-wjem-17-22){ref-type="supplementary-material"}). Among the analytic cohort, 632 patients (33%) had private insurance, 775 (40%) had public insurance, and 521 (27%) had no insurance. Patient demographics differed across the groups ([Table 1](#t1-wjem-17-22){ref-type="table"}). For example, compared to patients with private insurance, those with no insurance were more likely to be male, non-Hispanic black and smoker, and less likely to have a primary care physician (all p\<0.001).

Likewise, chronic asthma factors and management differed across the groups. Compared to patients with private insurance, those with public insurance or no insurance were more likely to have a marker of chronic asthma severity (i.e., ≥2 ED visits in a one-year period) (35%, 49%, and 45%, respectively; p\<0.001; [Table 1](#t1-wjem-17-22){ref-type="table"}). Despite their higher chronic severity, those with no insurance were less likely to have received guideline-recommended chronic asthma care before the ED visit -- i.e., lower use of ICS (41%, 41%, and 29%; p\<0.001) and lower utilization of asthma specialist care (9%, 10%, and 4%; p\<0.001). However, the proportion of patients who had received these two chronic asthma management measures was low across the groups.

By contrast, there were no clinically important differences in ED presentation or statistically significant differences in acute asthma management by insurance status ([Table 1](#t1-wjem-17-22){ref-type="table"}). However, even with the higher chronic asthma severity of patients with public insurance or no insurance, the proportion of patients newly prescribed ICS at ED discharge did not differ across the groups (12%, 12%, and 14%; p=0.57). In multivariable models adjusting for potential confounding factors and patient clustering, these results did not change materially ([Table 2](#t2-wjem-17-22){ref-type="table"}).

DISCUSSION
==========

In this multicenter study of ED adult patients with asthma exacerbation, we found significant discrepancies in chronic asthma severity and management by insurance status. Specifically, compared to patients with private insurance, those with public insurance or no insurance had a higher risk of frequent ED visits (≥2 visits during the preceding year). Yet, even with the higher chronic asthma severity, those with no insurance were less likely to have received guideline-recommended chronic asthma care. By contrast, ED asthma treatment did not differ across the insurance groups. However, at ED discharge, patients with public insurance or no insurance were, despite their much higher chronic severity, equally likely to be newly prescribed ICS.

Our findings were disappointingly similar to those of our previous multicenter study of 1,019 adult ED patients with asthma exacerbation in the late 1990s.[@b5-wjem-17-22] With the use of a similar design and setting, the previous study found that uninsured patients received suboptimal longitudinal care prior to their ED visits, despite their higher chronic severity. These observations paralleled another multicenter study of 965 children presenting to the ED with asthma exacerbation in the same period.[@b15-wjem-17-22] Additionally, in the community setting, studies have reported that patients with public insurance had fewer prescriptions of ICS,[@b21-wjem-17-22] difficulties with scheduling outpatient care,[@b22-wjem-17-22] and higher rates of ED visits for asthma exacerbation.[@b23-wjem-17-22],[@b24-wjem-17-22] To our knowledge, our multicenter study is the largest study to have investigated chronic and acute asthma management disparities by insurance status among ED patients. Our data corroborate these findings and extend them by demonstrating persistent disparity not only in the use of ICS but also in utilization of specialist care.

The reasons for the disproportionate healthcare-related disparity is likely multifactorial. Potential explanations include differences in patient demographics (e.g., race/ethnicity) and socioeconomic status (e.g., income). However, our inferences did not change even after adjusting for these factors. Alternatively, insurance status may be an identifiable surrogate marker for many patient and health system factors -- e.g., patient's health beliefs, self-management knowledge, and access to preventive care.[@b25-wjem-17-22]

LIMITATIONS
===========

This study has several potential limitations. First, we relied on chart review for data collection; therefore, error in data measurement is possible. For example, our methods of assigning insurance status may have led to misclassification. However, the use of medical records is likely to be more accurate than patient self-report.[@b26-wjem-17-22] Additionally, although we did not measure interrater agreement in this study, we used a previously-applied standardized data collection system with uniform definitions and rigorous training, which achieved a high inter-observer agreement (*k* coefficients, 0.6--1.0) in our recent study.[@b27-wjem-17-22] Second, as with any observational studies, the observed associations do not necessarily prove causality and might be confounded by unmeasured factors (e.g., access to ambulatory care, inter-hospital practice variations). However, we addressed this concern, at least partially, by accounting for clustering. Lastly, the EDs that composed this study were mainly urban, academic centers. This study setting resulted in a high proportion of patients with public insurance or no insurance as well as urban-dwelling minorities. However, our observations might not be generalized to rural, community EDs where asthma morbidity is also high.[@b28-wjem-17-22]

CONCLUSION
==========

In this large multicenter study of 1,928 ED patients with asthma exacerbation, we found an ongoing disparity in disease burden and management by insurance status. Compared to patients with private insurance, those with public insurance or no insurance had a greater risk of frequent ED visits. However, those with no insurance had less utilization of asthma controller medications and asthma specialist care. Although acute asthma treatment in the ED did not differ by insurance, patients with public insurance or no insurance were no more likely to be newly prescribed ICS at ED discharge despite their higher chronic severity. Additionally, we found that only a small subset of patients received guideline-recommended prevention-oriented asthma care regardless of their insurance. Therefore, it is unlikely that expanding insurance coverage through the Affordable Care Act alone can fully address the observed disparities in this high-risk population. Our data should encourage policymakers and clinicians to improve access to asthma specialists and promote greater implementation of the evidenced-based asthma guidelines.[@b3-wjem-17-22],[@b4-wjem-17-22]
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###### 

Patient characteristics and emergency department course, according to primary insurance status.

  Patient characteristics                                                        Private insurance (n=632; 33%)   Public insurance (n=775; 40%)   No insurance (n=521; 27%)       P value
  ------------------------------------------------------------------------------ -------------------------------- ------------------------------- ------------------------------- ---------
  Demographics                                                                                                                                                                    
   Age (y), median (IQR)                                                         34 (25--45)                      35 (25--45)                     33 (25--45)                     0.38
    18--29                                                                       249 (39)                         267 (34)                        203 (39)                        
    30--39                                                                       145 (23)                         207 (27)                        129 (25)                        
    40--54                                                                       238 (38)                         301 (39)                        189 (36)                        
   Male sex                                                                      230 (36)                         267 (35)                        285 (55)                        \<0.001
   Body mass index, median (IQR)[\*](#tfn2-wjem-17-22){ref-type="table-fn"}      31 (26--37)                      31 (26--38)                     28 (24--34)                     \<0.001
   Race/ethnicity[†](#tfn3-wjem-17-22){ref-type="table-fn"}                                                                                                                       \<0.001
    Non-Hispanic white                                                           170 (27)                         107 (14)                        99 (19)                         
    Non-Hispanic black                                                           297 (47)                         414 (53)                        291 (56)                        
    Hispanics                                                                    103 (16)                         184 (24)                        88 (17)                         
    Other                                                                        30 (5)                           20 (3)                          8 (2)                           
   Median household income estimated from ZIP code, median (IQR)                 \$39,327 (\$28,337--\$57,004)    \$32,733 (\$25,967--\$45,137)   \$34,167 (\$25,991--\$46,377)   \<0.001
   Having primary care physician                                                 450 (71)                         506 (65)                        189 (36)                        \<0.001
   Active smoker                                                                 160 (25)                         265 (34)                        203 (39)                        \<0.001
  Chronic asthma factors                                                                                                                                                          
   Ever hospitalized for asthma                                                  202 (32)                         314 (41)                        151 (29)                        \<0.001
   Ever intubated for asthma                                                     70 (11)                          123 (16)                        47 (9)                          0.01
   ED visit for asthma in past 12 months                                         219 (35)                         381 (49)                        235 (45)                        \<0.001
   Hospitalization for asthma in past 12 months                                  74 (12)                          150 (19)                        63 (12)                         \<0.001
  Chronic asthma care                                                                                                                                                             
   Current use of oral corticosteroids                                           86 (14)                          100 (13)                        53 (10)                         0.17
   Current use of ICS                                                            259 (41)                         315 (41)                        153 (29)                        \<0.001
   Current use of long-acting β-agonist                                          168 (27)                         213 (27)                        87 (17)                         \<0.001
   Current use of leukotriene modifiers                                          82 (13)                          102 (13)                        31 (6)                          \<0.001
   Seen by asthma specialist in past 12 months                                   55 (9)                           78 (10)                         21 (4)                          \<0.001
  ED presentations                                                                                                                                                                
   Duration of symptoms                                                                                                                                                           
    ≤3 hours prior to ED arrival                                                 53 (8)                           78 (10)                         54 (10)                         0.40
   Vital signs                                                                                                                                                                    
    Initial respiratory rate (breaths/min), median (IQR)                         20 (18--22)                      20 (18--22)                     20 (18--22)                     0.04
    Initial oxygen saturation (%), median (IQR)                                  98 (96--99)                      98 (96--99)                     97 (95--99)                     0.01
   Initial PEF (L/min), median (IQR)[‡](#tfn4-wjem-17-22){ref-type="table-fn"}   240 (160--320)                   230 (170--300)                  235 (175--300)                  0.81
   Concomitant medical disorders[§](#tfn5-wjem-17-22){ref-type="table-fn"}       94 (15)                          119 (15)                        51 (10)                         0.01
  ED treatment                                                                                                                                                                    
   Inhaled β-agonists                                                            626 (99)                         769 (99)                        516 (99)                        0.92
   Inhaled anticholinergics                                                      434 (69)                         571 (74)                        380 (73)                        0.09
   Systemic corticosteroids                                                      471 (75)                         613 (79)                        406 (78)                        0.08
   Intravenous magnesium                                                         53 (8)                           81 (10)                         42 (8)                          0.25
   Mechanical ventilation                                                        12 (2)                           8 (1)                           7 (1)                           0.38
  ED disposition                                                                                                                                                                  \<0.001
   Sent home                                                                     525 (83)                         488 (76)                        457 (88)                        
   Hospitalized                                                                  97 (15)                          172 (22)                        55 (11)                         
   Other (e.g., left against medical advice)                                     10 (2)                           15 (2)                          9 (2)                           
  ED length of stay (min), median (IQR)                                          183 (123--283)                   188 (120--301)                  175 (117--287)                  0.52
  Prescribed medications at ED discharge                                                                                                                                          
   Prescribed oral corticosteroids[¶](#tfn7-wjem-17-22){ref-type="table-fn"}     365 (70)                         448 (76)                        341 (75)                        0.01
   Newly prescribed ICS[\|\|](#tfn8-wjem-17-22){ref-type="table-fn"}             38 (12)                          46 (12)                         47 (14)                         0.57

*IQR,* interquartile ratio; *ICS,* inhaled corticosteroids; *ED,* emergency department, *PEF,* peak expiratory flow

Analyzed for 1,179 patients with body mass index available.

Percentages are not equal to 100 because of missing data.

Analyzed for 805 patients with initial PEF available.

Defined by pneumonia, congestive heart failure, pneumothorax, arrhythmia, sinusitis, and otitis media.

*ED,* emergency department; *IQR,* interquartile ratio; *ICS,* inhaled corticosteroids

Analyzed for discharged patients (n=1,570).

Analyzed for discharged patients who did not report recent use of inhaled corticosteroids (n=1,042).

###### 

Unadjusted and multivariable-adjusted associations of insurance status with study outcomes.

                                                                                    Private insurance   Public insurance   No insurance                                      
  --------------------------------------------------------------------------------- ------------------- ------------------ ------------------- --------- ------------------- ---------
  ED visit for asthma in past 12 months                                                                                                                                      
   Unadjusted model[\*](#tfn10-wjem-17-22){ref-type="table-fn"}                     reference           \-                 1.79 (1.40--2.27)   \<0.001   1.48 (1.13--1.94)   0.004
   Adjusted model[†](#tfn11-wjem-17-22){ref-type="table-fn"}                        reference           \-                 1.64 (1.29--2.10)   \<0.001   1.55 (1.17--2.05)   0.002
  Current use of ICS                                                                                                                                                         
   Unadjusted model[\*](#tfn10-wjem-17-22){ref-type="table-fn"}                     reference           \-                 0.97 (0.75--1.24)   0.79      0.58 (0.42--0.81)   0.001
   Adjusted model[†](#tfn11-wjem-17-22){ref-type="table-fn"}                        reference           \-                 0.85 (0.67--1.08)   0.19      0.63 (0.45--0.86)   0.004
  Evaluation by asthma specialist in past 12 months                                                                                                                          
   Unadjusted model[\*](#tfn10-wjem-17-22){ref-type="table-fn"}                     reference           \-                 0.97 (0.68--1.38)   0.86      0.43 (0.28--0.65)   \<0.001
   Adjusted model[†](#tfn11-wjem-17-22){ref-type="table-fn"}                        reference           \-                 0.93 (0.64--1.36)   0.70      0.52 (0.32--0.84)   0.008
  Use of systemic corticosteroids in the ED                                                                                                                                  
   Unadjusted model[\*](#tfn10-wjem-17-22){ref-type="table-fn"}                     reference           \-                 1.38 (1.10--1.74)   0.006     1.19 (0.94--1.51)   0.14
   Adjusted model[†](#tfn11-wjem-17-22){ref-type="table-fn"}                        reference           \-                 1.25 (0.98--1.60)   0.07      1.27 (0.98--1.64)   0.07
  Newly prescribed ICS at ED discharge[‡](#tfn12-wjem-17-22){ref-type="table-fn"}                                                                                            
   Unadjusted model[\*](#tfn10-wjem-17-22){ref-type="table-fn"}                     reference           \-                 0.74 (0.50--1.10)   0.14      0.86 (0.54--1.38)   0.54
   Adjusted model[†](#tfn11-wjem-17-22){ref-type="table-fn"}                        reference           \-                 0.73 (0.49--1.07)   0.10      0.91 (0.57--1.46)   0.70

*OR,* odds ratio; *CI,* confidence interval; *ED,* emergency department; *ICS,* inhaled corticosteroids

Unadjusted logistic regression model using the generalized estimating equations to account for patient clustering within EDs.

Multivariable logistic regression model using the generalized estimating equations to account for patient clustering within EDs, with adjusting for age, sex, race/ethnicity, estimated household income, and history of hospitalization and intubation for asthma exacerbation.

Analyzed for discharged patients who did not report recent use of inhaled corticosteroids (n=1,042).
